Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
SB 431542: Practical ALK5 Inhibitor Workflows
2026-08-31
Use SB 431542 to dissect TGF-β–dependent Smad2 signaling, glioma proliferation, immune modulation, and stem-cell lineage behavior with a workflow built around matched vehicle controls and orthogonal readouts. Its value is greatest when pathway suppression is separated from cytotoxicity and when ALK4/7 cross-reactivity is treated as an experimental variable.
-
SIS3: Reading Smad3 in Complex TGF-β Networks
2026-08-31
SIS3 is a selective Smad3 inhibitor for dissecting how TGF-β signals become context-specific transcriptional and fibrotic phenotypes. This article connects enhancer biology, microenvironmental signaling, and layered assay design to improve mechanistic interpretation in oncology and fibrosis research.
-
Morning Training Improves Endurance Adaptation in Mice
2026-08-30
Hesketh et al. show that endurance training during the early active phase produces faster and more efficient performance adaptation than training during the late active phase in female mice. The study separates acute time-of-day differences in capacity from the longer-term training response and identifies skeletal-muscle metabolic and contractile changes associated with early-active-phase training.
-
Nanoparticle Uptake by Human Corneal Cells
2026-08-29
This 2024 study shows how PLGA nanoparticle size and surface chemistry shape uptake by human corneal epithelial cells. Using a mucosa-integrated in vitro model and inhibitor studies, the authors identify energy-dependent uptake dominated by macropinocytosis and caveolae-mediated endocytosis, providing formulation guidance for topical ocular delivery.
-
PNU 74654: A Mechanism-First Wnt Inhibitor Guide
2026-08-28
PNU 74654 is a Wnt signaling pathway inhibitor for dissecting pathway activity, cell fate, and assay interpretation. This mechanism-first guide connects product handling with findings from skeletal muscle progenitor research while clarifying what the compound can—and cannot—demonstrate experimentally.
-
EdU Imaging Kits (488) for Disease-Model Assays
2026-08-28
EdU Imaging Kits (488) provide a precise way to measure DNA synthesis while preserving cellular architecture. This article explains how to apply EdU imaging to distinguish reduced proliferation from senescence-associated phenotypes in preeclampsia-derived stem cells.
-
Adult Stem Cell Protocols: Innovation and Translation
2026-08-27
Adult Stem Cells Methods and Protocols, Second Edition presents a reproducibility-centered framework for isolating, characterizing, culturing, and applying adult stem cells in regenerative research. Its main innovation is the integration of stepwise laboratory protocols with troubleshooting guidance and translational considerations, helping researchers connect cell preparation with tissue-engineering and therapeutic objectives.
-
Cyclic Pifithrin-α Hydrobromide: Assay Logic
2026-08-27
Cyclic Pifithrin-α hydrobromide is a p53 inhibitor for dissecting transcription-dependent apoptosis and DNA damage responses. This guide focuses on causal assay design, controls, and the limits of translating p53 perturbation into neuroinflammation research.
-
Measuring Drug Responses Beyond Cell Viability
2026-08-26
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these commonly interchangeable metrics capture different relationships between growth inhibition and cell death. The framework supports more rigorous cancer drug evaluation by separating cytostatic effects, cytotoxicity, and response timing rather than treating a single endpoint as a complete pharmacologic description.
-
JNK-IN-7 in Candida-Triggered Apoptosis Research
2026-08-26
JNK-IN-7 is a selective JNK inhibitor for separating c-Jun signaling from apoptosis and innate immune responses. This article translates Candida krusei BMEC findings into a phase-aware assay strategy while addressing covalent target engagement, concentration-dependent interpretation, and experimental limitations.
-
Dual-Action Inhibitors Reprogram p38α Dephosphorylation
2026-08-25
The reference study shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also reshape the activation loop to accelerate dephosphorylation by WIP1. This structure-guided finding offers a framework for designing inhibitors that combine direct kinase blockade with phosphatase-facilitated pathway shutdown.
-
ddATP Workflows for DNA Synthesis Termination
2026-08-25
ddATP enables controlled DNA synthesis termination in sequencing, polymerase assays, and mechanistic DNA repair studies. This guide translates its chain-termination chemistry into practical workflows, dose-finding strategies, and troubleshooting steps informed by research in mouse oocytes.
-
Substance P Workflows for NK1 Signaling Research
2026-08-24
Build cleaner Substance P experiments for pain transmission, neuroinflammation, and immune response modulation with fresh aqueous preparations, matched controls, and staged dose–response designs. A fluorescence-spectroscopy workflow from a 2024 study adds a practical quality-control perspective for recognizing and reducing biological background interference.
-
Cell Divisions Refine Drosophila Tissue Boundaries
2026-08-24
A 2026 Development study shows that ectodermal cell divisions have a dual mechanical role at the Drosophila mesectoderm–ectoderm boundary: they can challenge separation while also sharpening the interface. Combining mathematical modelling, live imaging, laser ablation, and cell tracking, the authors identify division-driven tissue fluidity as a previously unrecognized mechanism of boundary refinement.
-
U0126: MEK1/2 Inhibition in Cell Signaling
2026-08-23
U0126 is a selective, non-ATP-competitive MEK1/2 inhibitor for mapping ERK-dependent signaling, adaptive resistance, and cell-fate decisions. This practical guide covers dosing logic, pathway readouts, autophagy-related applications, and troubleshooting for reproducible cell-based experiments.